India, June 10 -- MAIA Biotechnology Inc. (MAIA), a clinical-stage biopharmaceutical company, on Wednesday, announced the expansion of the Phase 2 THIO-101 trial for Ateganosine in treating non-small cell lung cancer to a second clinical testing site in the U.S.
Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is an investigational, first-in-class telomere-targeting agent in development for the treatment of non-small cell lung cancer (NSCLC). Cancer cells often show telomeres immune against degradation, contributing to their continued survival and resistance to current chemotherapies. The drug targets these telomeres and triggers certain immune responses, leading to tumor regression.
The current Phase 2 expansion study evaluates ...